InventisBio (IVB HK): Synthetic Expert Call Transcript (24 Aug 2026)
Defensive Capital Measures: With cash and cash equivalents down to 640.0 million RMB as of June 30, 2026, InventisBioās updated HKEX listing...
114 Views
IPO Databook: InventisBio Co., Limitedļ¼ļ¼ (688382 HK) - Aug 2026
InventisBio Co., Limited, founded in 2013, is a biopharmaceutical company focused on oncology, autoimmune, and metabolic disorders with eight...
107 Views
Primer: InventisBio (IVB HK) - Aug 2026
InventisBio is a clinical-stage biotechnology company with a promising pipeline of innovative drug candidates targeting major diseases,...
90 Views
InventisBio (ēę¹ēē©) A+H: Moderate Innovation in Crowded Spaces
āChina-based biotech InventisBio seeks to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its drug pipelines,...
319 Views
Pre-IPO InventisBio (A/H Listing) - The Success of Key Products Will Lead to a Surge in Valuation
āInventisBio's differentiated R&D strategy/promising pipeline will lead to higher valuation upside compared to peers. D-2570 is the key driving...
224 Views